Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) — Sponsor Intelligence | 94 EU Trials

Filter these 94 trials by condition, phase, country and more.

Open in Search →

94 Registered trials

46 Recruiting

17 Completed trials

14 Countries active

123 Unique IMPs

100% Results reported

Phase III

Phase II

Phase IV

Phase III: 15 Phase II/III: 3 Phase II: 17 Phase I/II: 7 Phase III/IV: 8 Phase IV: 27 Phase I: 3 Phase I (Other): 8 Phase I (FiH): 4 Other: 2

Oversight events:

2 serious breaches 1 temporary halt across 3 trials

View oversight register →

100%

17 of 17 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Glioblastoma multiforme 2 Rheumatoid arthritis 1 Cancer pain 1 Laser speckle contrast imaging 1 Prostate cancer metastatic 1 Complex regional pain syndrome 1 Oxytocin 1 Trigeminal nerve disorder 1 Cardiac sarcoidosis 1 Migraine 1

Top IMPs

IRINOTECAN HYDROCHLORIDE TRIHYDRATE 5 FLUOROURACIL 4 FOLINIC ACID 4 OXALIPLATIN 4 NIVOLUMAB 3 PEMBROLIZUMAB 3 (S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHYLCARBAMOYL)-QUINOLIN-6-YL)(METHYL)AMINO)-PROPYL)PIPERAZIN-1-YL)-2-OXOETHYL)-68GA-[1,4,7,10]-TETRAAZACYCLODODECANE-1,4,7-TRIYL)TRIACETATE 2 [AL[18F]F]FAPI-74 2 ALGLUCOSIDASE ALFA 2 AMOXICILLIN 2 AUTOLOGOUS DENDRITIC CELLS LOADED WITH ALLOGENIC ALLOGENEIC LYSATE OF MESOTHELIOMA CELL LINES 2 AVALGLUCOSIDASE ALFA 2

All trials — page 4

94 total

Reduction of blood loss in pediatric surgical procedures around the hip - A trial with tranexamic acid Recruiting

2024-516324-34-01 Phase IV 1 country
Improving Peptide Receptor Radionuclide Therapy with PARP inhibitors Recruiting

2024-513007-14-00 Phase I (Other) 1 country
Phase I study of 225Ac-PSMA I&T in prostate cancer Recruiting

2024-513729-22-01 1 country
Doxapram versus placebo in preterm newborns: An international double blinded multicenter randomized controlled trial Recruiting

2024-515625-29-00 Phase III 2 countries DOXAPRAM HYDROCHLORIDE MONOHYDRATE
A phase 1B of crizotinib either in combination or as single agent in pediatric patients with ALK, ROS1 or MET positive malignancies Recruiting

2023-504880-18-00 Phase I/II 9 countries CRIZOTINIB; TEMSIROLIMUS
Comparing the effectiveness of our tailor-made management approach with routine care from a clinical, patient's as well as an economic point… Ended

2024-511530-12-01 Phase IV 1 country ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; FILGOTINIB; GOLIMUMAB; HYDROXYCHLORO…
Safe Stop ipi-nivo Ended

2024-516938-34-00 Phase III 1 country IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB
MAD Ended

2024-516379-34-00 Phase IV 1 country ATROPINE SULFATE
[18F]F-FAPI PET-CT to Identify Carcinoma of Unknown Primary origin Ended

2023-505592-69-00 Phase III 1 country [AL[18F]F]FAPI-74
KetCRPS-2 Ended

2024-511877-31-00 Phase IV 1 country ESKETAMINE HYDROCHLORIDE
Bosutinib in pediatric CML patients Ended

2023-504311-32-00 Phase I/II 5 countries BOSUTINIB
The rimegePant in RElation to obeSiTy in mIGrainE study Ended

2024-513359-34-00 Phase IV 1 country CAPSAICIN
THE (COST)EFFECTIVENESS OF NEOADJUVANT FOLFIRINOX VERSUS NEOADJUVANT GEMCITABINE BASED CHEMORADIOTHERAPY AND ADJUVANT GEMCITABINE FOR (BORDE… Ended

2024-516260-29-00 Phase III 1 country FLUOROURACIL; FOLINIC ACID; GEMCITABINE HYDROCHLORIDE; IRINOTECAN HYDROCHLORIDE …
Optimizing reversal of HIV latency with combination therapy (pyrimethamine, lenalidomide, panobinostat) Ended

2024-511192-15-00 Phase II 1 country
Phase 0 lead-in trial of Pitavastatin in primary and recurrent Glioblastoma patients Ended

2023-505743-38-00 Phase I (Other) 1 country
Nivolumab during active surveillance after neoadjuvant chemoradiation for esophageal cancer: SANO-3 study Ended

2024-513635-24-00 Phase II/III 1 country NIVOLUMAB
Safety and efficacy of adding immunotherapy combined with stereotactic radiotherapy in patients with limited metastatic pancreatic cancer (M… Ended

2024-514598-23-00 Phase I/II 1 country MYCOBATERIUM OBUENSE, STRAIN NCTC 13365, HEAT-KILLED
Botulinum toxin (BOTOX®) to prevent post-operative pancreatic fistula in patients who undergo distal pancreatectomy Ended

2024-517267-23-00 Phase I (FiH) 1 country BOTULINUM TOXIN TYPE A
FUnctional selection of advanced breast cancer patients for Talazoparib treatment Using the REpair Capacity (RECAP) test: The FUTURE trial Ended

2024-518036-36-03 Phase IV 1 country TALAZOPARIB
Trampoline study Ended

2024-512544-27-00 Phase IV 1 country
INTERACT stomach Ended

2024-516265-37-00 Phase I 1 country
INTERACT MESO: Intraperitoneal Paclitaxel for Patients with Primary Malignant Peritoneal Mesothelioma – a Phase I/II Dose Escalation and Saf… Ended

2024-516738-36-00 Phase I (Other) 1 country

Showing 73–94 of 94 trials

← All sponsors A–Z